This NIDA grant is for the purpose of advancing the development of safe and effective medications for Substance Use Disorders (SUDs). The National Institute on Drug Abuse (NIDA) is offering this Translational Avant-Garde Award to support dedicated basic and/or clinical researchers in translating research discoveries into new treatments for SUDs, including those stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Proposed medications can be small molecules or biologics, such as vaccines and recombinant therapeutic proteins. Applications may focus on treating SUDs, or specific clinical manifestations like withdrawal, craving, or relapse. The grant also supports developing new formulations of existing medications or novel combinations of current treatments for SUDs.
Opportunity ID: 109473
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-12-010 |
| Funding Opportunity Title: | 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 29, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Feb 21, 2012 |
| Current Closing Date for Applications: | Feb 21, 2012 |
| Archive Date: | Mar 23, 2012 |
| Estimated Total Program Funding: | $3,000,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments State governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments City or township governments Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of Substance-Use Disorders (SUDs). Through this FOA, the National Institute on Drug Abuse (NIDA) is committed to advancing the development of safe and efficacious medications for the treatment of SUDs stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Medications can be either small molecules or biologics. Biologics include vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the treatment of substance use (i.e., abuse or dependence) disorders and specific clinical manifestations of these disorders such as withdrawal, craving, or relapse.Applications that focus on the development of new formulations of marketed medications that are available for other indications, or new combinations of existing medications that hold promise for the treatment of SUDs, are also within the scope of this RFA. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-010.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.279 | ADOBE-FORMS-B1 | ADOBE-FORMS-B1 | PKG00067771 | Jan 21, 2012 | Feb 21, 2012 | View |
Package 1
Mandatory forms
109473 RR_SF424_1_2-1.2.pdf
109473 PHS398_ResearchPlan_1_3-1.3.pdf
109473 PHS398_CoverPageSupplement_1_4-1.4.pdf
109473 RR_KeyPersonExpanded_1_2-1.2.pdf
109473 RR_OtherProjectInfo_1_3-1.3.pdf
109473 PerformanceSite_1_4-1.4.pdf
Optional forms
109473 PHS_CoverLetter_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
